20/21 November 2019
GMP News No. 764
28 July 2006
European Compliance Academy initiates
In its inaugural meeting in early June at the PEI in Langen, Germany, the working group reviewed the current situation of RMMs in Europe and defined a work plan.
The photo shows from left to right:
One of the current issues the group identified is the lack of standardisation for the submission of RMMs. The group also considers the integration of certain methods into the European Pharmacopoeia chapter 5.1.6 as critical because it possibly sets a wrong focus on these tests only. In addition, the use of RMMs for marketed products is discouraged by the Type II Change effort. The group also voiced concerns about the inappropriate methods occasionally requested by the authorities - like classical EP sterility tests for cell therapy products. In general it sees a clear forward path for using RMMs for new submissions.
To develop a work plan also representing the industry's point of view the group conducted a survey in one of ECA's Masterclasses and over the internet. The result representing close to 40 major European pharmaceutical companies and biotech start-ups across Europe showed that many companies plan on introducing RMMs in the next 1-3 years, and that most of them want to apply them for environmental monitoring and to focus on quantitative methods. Most companies also expressed that there's not enough regulatory support to drive a change quickly and that a clearer regulatory guidance would accelerate methods introduction. According to the survey companies also perceive the approval process as complex, thus delaying introduction. In that respect a clear expectation for adopting RMMs on the authorities' side would strongly influence many companies' thinking.
To help both authorities and industry get a better understanding of the
requirements for the introduction of RMMs and to provide them with
guidance based on case studies and available experience, the group will
establish a Best Practice Guide. In two main chapters the guide will
concentrate on traditional drugs and new drugs with their particular
aspects and requirements. "We also want national agencies and
inspectorates to be involved. We'll thus plan on discussing first drafts
with representatives from EMEA, EDQM and national authorities", said
Mike Edgington, Director for Regulatory Affairs, ECA. To share information
from the guide with both sides the ECA will also organise webinars and
courses. In addition the group plans on publishing articles in European
pharmaceutical industry publications.
find out more about the Working Group, a GMP Webinar was recorded on 7
July 2006 at the ECA Advisory Board Meeting. You can watch the recorded
Webinar for free. All you need is a fast internet connection, a sound card
in your PC and a Media Player like Windows Media Player or the RealPlayer.
Start Mike Edgington's presentation here.
If you are interested in contributing to the RMM Working Group, please
send a mail to